Evidence map›Paper›PMID 28630710›Full record

ArticleJournal of materials chemistry. B2017

HDAC Inhibitor Conjugated Polymeric Prodrug Micelles for Doxorubicin Delivery.

Suchithra A Senevirathne, Katherine E Washington, Jason B Miller, Michael C Biewer, David Oupicky, Daniel J Siegwart, Mihaela C Stefan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of materials chemistry. B, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Suchithra A SenevirathneDepartment of Chemistry, University of Texas at Dallas, Richardson, TX, USA.
Katherine E WashingtonDepartment of Chemistry, University of Texas at Dallas, Richardson, TX, USA.
Jason B MillerDepartment of Biochemistry, University of Texas Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, TX, USA.
Michael C BiewerDepartment of Chemistry, University of Texas at Dallas, Richardson, TX, USA.
David OupickyCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, USA.
Daniel J SiegwartDepartment of Biochemistry, University of Texas Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, TX, USA.
Mihaela C StefanDepartment of Chemistry, University of Texas at Dallas, Richardson, TX, USA.

Funding

Nanoparticles based on histone deacetylase inhibitors for combination treatmentsR21EB019175 · NIBIB · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUPICKY, DAVID · 2015 to 2016
$430k
NIBIB NIH HHS R21 EB019175
6 · The paper itself

Abstract

Amphiphilic diblock copolymers bearing histone deacetylase inhibitors (HDACi) (4-phenyl butyric acid and valproic acid) were synthesized by the ring-opening polymerization of γ-4-phenylbutyrate-ε-caprolactone (PBACL), γ-valproate-ε-caprolactone (VPACL), and ε-caprolactone (CL) from a poly(ethylene glycol) macroinitiator (PEG). These amphiphilic diblock copolymers self-assembled into stable pro-drug micelles and demonstrated excellent biocompatibility. High loading of doxorubicin (DOX) up to 5.1 wt% was achieved. Optimized micelles enabled sustained drug release in a concentration-dependent manner over time to expand the therapeutic window of cytotoxic small molecule drugs.

Identifiers

PMID28630710
PMCPMC5473365

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.